Will These Stocks Breakout? Cyclacel Pharmaceuticals Inc (CYCC), Alliance One International, Inc. (AOI) and Navidea Biopharmaceuticals Inc (NAVB)

Posted by Saimoon May 8, 2015 0 Comment 413 views


New York, NY – GDP INSIDER  –  05/08/2014.

This article discusses three companies: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), Alliance One International, Inc. (NYSE:AOI) and Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) continued its downward trend yesterday with the stock closing down 9.52% or $0.080 to finish the day at a closing price of $0.760 on lower than average trading volume of 0.675 million, compared to its three month average trading volume of 1.19 million. The cancer treatment therapies developer has been falling steadily for the last one year with the stock down 76.90%, but has been starting to gain back some of these losses since the beginning of the year with the stock up 8.59% year to date. However, with the stock just passing a positive MACD crossover and RSI still relatively low at 31, the stock has significant upward potential, making it a hold and speculative buy at this time.

What Does The Future Hold For Cyclacel Pharmaceuticals Inc? Read Our Free CYCC Analysis To Know More.

Alliance One International, Inc. (NYSE:AOI) continued to decline yesterday with the stock losing 6.98% or $0.09 to close the day at $1.20 with only 0.431 million shares changing hands compared to its three month average trading volume of 0.619 million. The shares are down by 53% over the past one year but are up over 13% in the past three months. The 52-week range is $0.53 to $2.87.  The technical indicators are not pointing to move in the stock one way or the other. However, with RSI of 43 and bearish MACD divergence, the stock may continue to fall in the near term. At this time, it is a risky buying opportunity, but one that may be worth it over the medium term.

Do Alliance One International, Inc Fundamentals Support Significant Medium Term Gains? Click Here For Free AOI Analysis.

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) reversed its recent decline yesterday gaining nine cents to close the day $1.33, a 7.26% increase in value from its previous closing price of $1.24 on slightly higher than average trading volume of 0.679 million compared with its three month average trading volume of 0.517 million. The stock has not been performing well over the last 26 weeks as the share price has decreased over 30%, underperforming the S&P 500 which is up 1.41% for the same period. If the stock can maintain its recent climb, it could have a chance of making its one year target estimate of $4.56 and with a converging MACD, the stock is a long term hold or a potential buy at this time.

Does Navidea Biopharmaceuticals Inc Offer A Profitable Investment Opportunity? Click Here For Free NAVB Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment